TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Recommendation of “Buy” from Brokerages

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) have been assigned an average rating of “Buy” from the nine research firms that are covering the company, Marketbeat.com reports. Seven analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $11.79.

A number of brokerages have recently issued reports on TLSI. Northland Securities started coverage on shares of TriSalus Life Sciences in a research report on Friday, October 25th. They issued an “outperform” rating and a $12.50 price target on the stock. Oppenheimer assumed coverage on shares of TriSalus Life Sciences in a report on Monday, September 16th. They issued an “outperform” rating and a $10.00 target price on the stock. Northland Capmk upgraded TriSalus Life Sciences to a “strong-buy” rating in a report on Friday, October 25th. Cantor Fitzgerald initiated coverage on TriSalus Life Sciences in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 price objective on the stock. Finally, Roth Capital raised TriSalus Life Sciences to a “strong-buy” rating in a research note on Monday, November 11th.

Insider Activity at TriSalus Life Sciences

In other TriSalus Life Sciences news, major shareholder Equity Ab Frankenius purchased 62,972 shares of TriSalus Life Sciences stock in a transaction that occurred on Tuesday, December 17th. The stock was acquired at an average price of $3.97 per share, with a total value of $249,998.84. Following the transaction, the insider now owns 6,230,748 shares in the company, valued at $24,736,069.56. This trade represents a 1.02 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders bought 70,012 shares of company stock valued at $281,235 in the last three months. Corporate insiders own 32.80% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Virtu Financial LLC bought a new stake in shares of TriSalus Life Sciences during the third quarter worth about $92,000. Geode Capital Management LLC increased its holdings in TriSalus Life Sciences by 45.4% during the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after purchasing an additional 62,542 shares in the last quarter. Vestcor Inc purchased a new stake in shares of TriSalus Life Sciences in the third quarter worth approximately $108,000. MSD Partners L.P. bought a new position in shares of TriSalus Life Sciences in the third quarter valued at approximately $184,000. Finally, Walleye Capital LLC purchased a new position in shares of TriSalus Life Sciences during the third quarter valued at approximately $66,000. 2.58% of the stock is owned by institutional investors.

TriSalus Life Sciences Price Performance

TriSalus Life Sciences stock opened at $4.90 on Thursday. The stock’s 50 day moving average is $4.38 and its 200 day moving average is $4.79. TriSalus Life Sciences has a one year low of $3.50 and a one year high of $10.42. The firm has a market cap of $149.42 million, a P/E ratio of -1.97 and a beta of 0.51.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.